Literature DB >> 21430363

On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.

V Daniëls1, V Baekelandt, J-M Taymans.   

Abstract

Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Although PD has long been considered a purely sporadic disorder, genetic research has revealed an underlying genetic cause in at least 10% of all PD cases. To date, mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common cause of familial PD. Moreover, given the strong clinical and neuropathological similarities between LRRK2 PD and the sporadic forms of the disease, the notion is supported that the unravelling of the molecular pathways underlying LRRK2 PD will greatly contribute to our general understanding of PD. Therefore, intense research efforts have been focused on the understanding of the physiological function of LRRK2 and its relation to PD. To date, progress has been made in these fields based on the study of LRRK2 cell culture models, the identification of LRRK2 interaction partners and kinase substrates and the generation of LRRK2 animal models. In this review, the current insights into the cellular role of LRRK2 are discussed. The overview reveals a potential involvement of LRRK2 in major cell signalling pathways including apoptosis, cytoskeleton dynamics, protein translation, mitogen-activated protein kinase signalling and specific dopaminergic functions, consistent with its proposed role as a signal transduction protein.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430363     DOI: 10.1159/000324488

Source DB:  PubMed          Journal:  Neurosignals        ISSN: 1424-862X


  15 in total

Review 1.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

2.  Drug discovery in Parkinson's disease-Update and developments in the use of cellular models.

Authors:  Gaia Skibinski; Steven Finkbeiner
Journal:  Int J High Throughput Screen       Date:  2011-06

3.  Characterization of TAE684 as a potent LRRK2 kinase inhibitor.

Authors:  Jinwei Zhang; Xianming Deng; Hwan Geun Choi; Dario R Alessi; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2012-01-28       Impact factor: 2.823

4.  Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor.

Authors:  John M Hatcher; Jinwei Zhang; Hwan Geun Choi; Genta Ito; Dario R Alessi; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2015-04-07       Impact factor: 4.345

5.  LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.

Authors:  Kelly M Hinkle; Mei Yue; Bahareh Behrouz; Justus C Dächsel; Sarah J Lincoln; Erin E Bowles; Joel E Beevers; Brittany Dugger; Beate Winner; Iryna Prots; Caroline B Kent; Kenya Nishioka; Wen-Lang Lin; Dennis W Dickson; Christopher J Janus; Matthew J Farrer; Heather L Melrose
Journal:  Mol Neurodegener       Date:  2012-05-30       Impact factor: 14.195

6.  Highly dynamic exon shuffling in candidate pathogen receptors ... what if brown algae were capable of adaptive immunity?

Authors:  Antonios Zambounis; Marek Elias; Lieven Sterck; Florian Maumus; Claire M M Gachon
Journal:  Mol Biol Evol       Date:  2011-12-05       Impact factor: 16.240

7.  GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.

Authors:  Alastair D Reith; Paul Bamborough; Karamjit Jandu; Daniele Andreotti; Lucy Mensah; Pamela Dossang; Hwan Geun Choi; Xianming Deng; Jinwei Zhang; Dario R Alessi; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2012-07-07       Impact factor: 2.823

8.  Brain Penetrant LRRK2 Inhibitor.

Authors:  Hwan Geun Choi; Jinwei Zhang; Xianming Deng; John M Hatcher; Matthew P Patricelli; Zheng Zhao; Dario R Alessi; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2012-06-18       Impact factor: 4.345

9.  Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.

Authors:  Paul Davies; Kelly M Hinkle; Nour N Sukar; Bryan Sepulveda; Roxana Mesias; Geidy Serrano; Dario R Alessi; Thomas G Beach; Deanna L Benson; Charles L White; Rita M Cowell; Sonal S Das; Andrew B West; Heather L Melrose
Journal:  Biochem J       Date:  2013-07-01       Impact factor: 3.857

10.  Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways.

Authors:  Lauran Reyniers; Maria Grazia Del Giudice; Laura Civiero; Elisa Belluzzi; Evy Lobbestael; Alexandra Beilina; Giorgio Arrigoni; Rita Derua; Etienne Waelkens; Yan Li; Claudia Crosio; Ciro Iaccarino; Mark R Cookson; Veerle Baekelandt; Elisa Greggio; Jean-Marc Taymans
Journal:  J Neurochem       Date:  2014-07-14       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.